Viridian Therapeutics, Inc.
VRDN
$13.13
$0.483.79%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 0.00% | 19.44% | 0.00% | -26.53% | -31.43% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.00% | 19.44% | 0.00% | -26.53% | -31.43% |
| Cost of Revenue | 49.13% | -- | 41.07% | -19.31% | 306.35% |
| Gross Profit | -49.15% | 19.44% | -41.81% | 19.29% | -307.26% |
| SG&A Expenses | -52.77% | -31.10% | -16.60% | -31.18% | 234.82% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 22.35% | 62.91% | 21.76% | -22.88% | 45.51% |
| Operating Income | -22.38% | -62.97% | -21.78% | 22.87% | -45.68% |
| Income Before Tax | -19.24% | -60.91% | -18.03% | 28.77% | -46.03% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -19.24% | -60.91% | -18.03% | 28.77% | -46.03% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -19.24% | -60.91% | -18.03% | 28.77% | -46.03% |
| EBIT | -22.38% | -62.97% | -21.78% | 22.87% | -45.68% |
| EBITDA | -22.46% | -63.15% | -21.81% | 22.96% | -45.66% |
| EPS Basic | -175.36% | -5.75% | 20.05% | 50.75% | 92.63% |
| Normalized Basic EPS | 25.97% | -5.81% | 20.05% | 50.75% | -19.50% |
| EPS Diluted | -175.36% | -5.75% | 20.05% | 50.75% | 92.63% |
| Normalized Diluted EPS | 25.97% | -5.81% | 20.05% | 50.75% | -19.50% |
| Average Basic Shares Outstanding | 61.13% | 52.15% | 47.63% | 44.64% | 22.55% |
| Average Diluted Shares Outstanding | 61.13% | 52.15% | 47.63% | 44.64% | 22.55% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |